Matthew J Walters

Summary

Publications

  1. doi request reprint CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens
    Matthew J Walters
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, United States
    Immunol Lett 151:44-7. 2013
  2. doi request reprint Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    Matthew J Walters
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Pharmacol Exp Ther 335:61-9. 2010
  3. doi request reprint Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes
    Timothy J Sullivan
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Metabolism 62:1623-32. 2013
  4. doi request reprint Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels
    Robert D Berahovich
    ChemoCentryx, Inc, Mountain View, CA, USA
    Immunology 141:111-22. 2014

Collaborators

Detail Information

Publications4

  1. doi request reprint CCR9 inhibition does not interfere with the development of immune tolerance to oral antigens
    Matthew J Walters
    ChemoCentryx, Inc, 850 Maude Avenue, Mountain View, CA 94043, United States
    Immunol Lett 151:44-7. 2013
    ..These results highlight the inadequacy of genetic deletion of CCR9 when predicting the effects of pharmacological CCR9 inhibition on intestinal biology...
  2. doi request reprint Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease
    Matthew J Walters
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    J Pharmacol Exp Ther 335:61-9. 2010
    ..Analysis of the plasma level of drug associated with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation...
  3. doi request reprint Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes
    Timothy J Sullivan
    ChemoCentryx, Inc, Mountain View, CA 94043, USA
    Metabolism 62:1623-32. 2013
    ..The aim of this study was to provide a broad analysis of the various physiological changes occurring in mouse models of T2D in connection with pharmacological CCR2 inhibition...
  4. doi request reprint Endothelial expression of CXCR7 and the regulation of systemic CXCL12 levels
    Robert D Berahovich
    ChemoCentryx, Inc, Mountain View, CA, USA
    Immunology 141:111-22. 2014
    ..These studies suggest that endothelial CXCR7 regulates circulating CXCL12 levels and that CXCR7 inhibitors might be used to block CXCL12-mediated cell migration for therapeutic purposes. ..